Firms
Chiesi Ventures
Chiesi Ventures is a life-sciences venture investment firm established through a strategic collaboration between the Chiesi pharmaceutical group and Pappas Capital. It backs early-stage companies developing treatments, diagnostic tools and disease-management technologies for rare and orphan diseases. Its focus spans small molecules and biologics, advanced therapies, drug-delivery technologies and medical devices, with investment and company-development support in the United States and Europe. Its portfolio includes Glycomine, which develops therapies for rare metabolic disorders with neurological symptoms, and Minoryx Therapeutics, which develops treatments for rare central nervous system diseases. The published investment committee reflects the Chiesi and Pappas partnership, with Chiesi holding the majority.
- Founded
- 2014
- Type
- Venture capital
Funds0
No funds on record yet.
Team
Operations and support
Co-investing
abrdn Inc.
Glycomine$115M · 2025-04-16
Advent Life Sciences- Glycomine$115M · 2025-04-16
Asahi Kasei Therapeutics Corp.- Glycomine$33M · 2019-08-07
Asahi Kasei Ventures- Glycomine$115M · 2025-04-16
CTI Life Sciences Fund- Glycomine$115M · 2025-04-16
Minoryx Therapeutics€21M · 2018-09-26
- Minoryx Therapeutics€21M · 2018-09-26
Kurma Partners- Minoryx Therapeutics€21M · 2018-09-26
Mission BioCapital- Glycomine$35M · 2021-06-23
- Minoryx Therapeutics€21M · 2018-09-26
Ysios Capital- Minoryx Therapeutics€21M · 2018-09-26
